Clinical analysis demonstrates elevated plasma neurofilament light chain levels in Charcot-Marie-Tooth disease, indicating its potential as a blood biomarker for peripheral neuropathy.
There are currently no validated blood biomarkers for peripheral neuropathy. The significantly raised plasma NfL concentration in patients with CMT and its correlation with disease severity suggest that plasma NfL holds promise as a biomarker of disease activity, not only for inherited neuropathies but for peripheral neuropathy in general.
No takes yet. Share an insight, caveat, or question.
Sandelius et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: